Clostridium difficile infection and liver disease

Journal of Gastrointestinal and Liver Diseases

Volumn 19, Issue 3, 2010, Pages 303-310

  Musa, Saif ^a   Moran, Carl ^a   Rahman, Tony ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Clostridium difficile; Clostridium difficile infection enterocolitis; Epidemiology; Liver diseases; Pseudomembranous; Risk factors and treatment

Indexed keywords

ANTIBIOTIC AGENT; FIDAXOMICIN; METRONIDAZOLE; NITAZOXANIDE; RIFAXIMIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLON RESECTION; DISEASE PREDISPOSITION; FECES ANALYSIS; HEALTH CARE COST; HUMAN; LIVER DISEASE; PATHOGENESIS; PREVALENCE; REVIEW; RISK FACTOR;

CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; LIVER DISEASES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 78650152848     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Fournier G, Orgiazzi J, Lenoir B, Dechavanne M. Pseudomembranous colitis probably due to rifampicin. Lancet 1980; 1: 101.
2. Moriarty HJ, Scobie BA. Pseudomembranous colitis in a patient on rifampicin and ethambutol. N Z Med J 1980; 91: 294-295.
3. Bommelaer G, Larpent JL, Rumeau JL, Ribet A. Pseudomembranous colitis and rifampicin. Lancet 1980; 2: 1192.
4. Klaui H, Leuenberger P. Pseudomembranous colitis due to rifampicin. Lancet 1981; 2: 1294.
5. Saginur R, Fogel R, Begin L, Cohen B, Mendelson J. Splenic abscess due to Clostridium difficile. J Infect Dis 1983; 147: 1105.
6. Bajaj JS, Ananthakrishnan AN, Hafeezullah M, et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective. Am J Gastroenterol 2010; 105: 106-113.
7. Kawecki D, Chmura A, Pacholczyk M, et al. Detection of Clostridium difficile in stool samples from patients in the early period after liver transplantation. Transplant Proc 2007; 39: 2812-2815.
8. Albright JB, Bonatti H, Mendez J, et al. Early and late onset Clostridium difficile-associated colitis following liver transplantation. Transpl Int 2007; 20: 856-866.
9. Hashimoto M, Sugawara Y, Tamura S, et al. Clostridium difficile-associated diarrhea after living donor liver transplantation. World J Gastroenterol 2007; 13: 2072-2076.
10. Pomposelli JJ, Verbesey J, Simpson MA, et al. Improved survival after live donor adult liver transplantation (LDALT) using right lobe grafts: program experience and lessons learned. Am J Transplant 2006; 6: 589-598.
11. Gellad ZF, Alexander BD, Liu JK, et al. Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients. Transpl Infect Dis 2007; 9:276-280.
12. Stelzmueller I, Goegele H, Biebl M, et al. Clostridium difficile colitis in solid organ transplantation--a single-center experience. Dig Dis Sci 2007; 52:3231-3236.
13. Vanjak D, Girault G, Branger C, Rufat P, Valla DC, Fantin B. Risk factors for Clostridium difficile infection in a hepatology ward. Infect Control Hosp Epidemiol 2007; 28: 202-204.
14. Wong NA, Bathgate AJ, Bellamy CO. Colorectal disease in liver allograft recipients -- a clinicopathological study with follow-up. Eur J Gastroenterol Hepatol 2002; 14: 231-236.
15. Sakurai T, Hajiro K, Takakuwa H, Nishi A, Aihara M, Chiba T. Liver abscess caused by Clostridium difficile. Scand J Infect Dis 2001; 33: 69-70.
16. Gravel D, Miller M, Simor A, et al; Canadian Nosocomial Infection Surveillance Program. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis 2009; 48: 568-576.
17. Garcia-Tsao G, Surawicz CM. Editorial: Clostridium difficile infection: Yet another predictor of poor outcome in cirrhosis. Am J Gastroenterol 2010;105:114-116.
18. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007; 45:1543-1549.
19. Kyne L, Merry C, O'Connell B, Keane C, O'Neill D. Community-acquired Clostridium difficile infection. J Infect 1998; 36: 287-288.
20. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989-2995.
21. Bajaj JS, Zadvornova Y, Hafeezullah M, Saeian K. Clostridium difficile infection is associated with proton pump inhibitors in patients with cirrhosis. Hepatology 2007; 46: Suppl: 580A. (Abstract).
22. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46 (Suppl 1):S32-42.
23. Limaye AP, Turgeon DK, Cookson BT, Fritsche TR. Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile. J Clin Microbiol 2000; 38: 1696-1697.
24. Planche T, Aghaizu A, Holliman R, et al. Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis 2008; 8:777-784.
25. Samore MH, DeGirolami PC, Tlucko A, Lichtenberg DA, Melvin ZA, Karchmer AW. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis 1994; 18: 181-187.
26. Hove H, Tvede M, Mortensen PB. Antibiotic-associated diarrhoea, Clostridium difficile, and short-chain fatty acids. Scand J Gastroenterol 1996; 31: 688-693.
27. Barbut F, Petit JC. Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect 2001; 7:405-410.
28. Ito Y, Moriwaki H, Muto Y, Kato N, Watanabe K, Ueno K. Effect of lactulose on short-chain fatty acids and lactate production and on the growth of faecal flora, with special reference to Clostridium difficile. J Med Microbiol 1997; 46: 80-84.
29. Olthoff KM, Merion RM, Ghobrial RM, et al; A2ALL Study Group. Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg 2005; 242: 314-323.
30. Hellinger WC, Yao JD, Alvarez S, et al. A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation. Transplantation 2002; 73: 1904-1909.
31. Monaghan T, Boswell T, Mahida YR. Recent advances in Clostridium difficile-associated disease. Gut 2008; 57:850-860.
32. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254-1260.
33. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-2449.
34. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362:1071-1081.
35. Lighthouse J, Naito Y, Helmy A, et al. Endotoxinemia and benzodiazepine-like substances in compensated cirrhotic patients: a randomized study comparing the effect of rifaximine alone and in association with a symbiotic preparation. Hepatol Res 2004; 28:155-160.
36. Maclayton DO, Eaton-Maxwell A. Rifaximin for treatment of hepatic encephalopathy.Ann Pharmacother 2009; 43:77-84.
37. Neff G, Zacharias V, Kaiser TE, Gaddis A, Kemmer N. Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series. Liver Transpl 2010; 16:960-963.
38. West M, Pirenne J, Chavers B, et al. Clostridium difficile colitis after kidney and kidney-pancreas transplantation. Clin Transplant 1999; 13: 318-323.
39. Bárány P, Stenvinkel P, Nord CE, Bergström J. Clostridium difficile infection--a poor prognostic sign in uremic patients? Clin Nephrol 1992; 38: 53-57.
40. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 345-351.
41. Geissler EK, Schlitt HJ. Immunosppression for liver transplantation Gut 2009; 58:452-463.
42. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171:33-38.
43. Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis 2006; 43:1272-1276.
44. Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother 2007; 51:2883-2887.
45. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxböck F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002; 30:1118-1122.
46. Kalaitzakis E, Bjornsson E. Inadequate use of proton-pump inhibitors in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2008; 20: 512-518.
47. Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 2008; 190:2505-2512.
48. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005; 18: 247-263.
49. Zhao HY, Wang HJ, Lu Z, Xu SZ. Intestinal microflora in patients with liver cirrhosis. Chin J Dig Dis 2004; 5: 64-67.
50. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441-1449.
51. Li L, Wu Z, Ma W, Yu Y, Chen Y. Changes in intestinal microflora in patients with chronic severe hepatitis. Chin Med J (Engl) 2001; 114: 869-872.
52. Kirpich IA, Solovieva NV, Leikhter SN, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008; 42: 675-682.
53. Warny M, Vaerman JP, Avesani V, Delmée M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62: 384-389.
54. Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: New challenges from an established pathogen. Cleve Clin J Med 2006; 73:187-197.
55. Doron S, Ruthazer R, Werner BG, Rabson A, Snydman DR. Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes. Transplantation 2006; 81: 697-703.
56. Muñoz P, Giannella M, Alcalá L, et al. Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer? J Heart Lung Transplant 2007 26:907-914.
57. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004; 171: 51-58.
58. Health Protection Agency. Clostridium difficile infection: How to deal with the problem, 2009. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1232006607827 (accessed July 2010).
59. Kuijper EJ, Coignard B, Tüll P; ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006; 12 (Suppl 6): 2-18.
60. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of america (shea) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455.
61. Niemczyk M, Leszczyńiski P, Wyzgał J, Paczek L, Krawczyk M, Luczak M. Infections caused by Clostridium difficile in kidney or liver graft recipients. Ann Transplant 2005; 10: 70-74.
62. Arslan H, Inci EK, Azap OK, Karakayali H, Torgay A, Haberal M. Etiologic agents of diarrhea in solid organ recipients. Transpl Infect Dis 2007; 9:270-275.
63. Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) 1988; 67:132-143.
64. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235: 363-372.
65. García-Lechuz JM, Hernangómez S, Juan RS, Peláez T, Alcalá L, Bouza E. Extra-intestinal infections caused by Clostridium difficile. Clin Microbiol Infect 2001; 7: 453-457.
66. De Leeuw P, de Mot H, Dugernier T, Wautelet J, Bohy E, Delmée M. Primary infection of ascitic fluid with Clostridium difficile. J Infect 1990; 21: 77-80.
67. Guingrich JA, Kuhlman JE. Colonic wall thickening in patients with cirrhosis: CT findings and clinical implications. AJR Am J Roentgenol 1999; 172: 919-924.
68. Bauer MP, Kuijper EJ, van Dissel JT; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15:1067-1079.
69. Bauer MP, van Dissel JT, Kuijper EJ. Clostridium difficile: controversies and approaches to management. Curr Opin Infect Dis 2009; 22:517-524.
70. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992; 117:297-302.
71. Hermsen JL, Dobrescu C, Kudsk KA. Clostridium difficile infection: a surgical disease in evolution. J Gastrointest Surg 2008; 12:1512-1517.
72. Synnott K, Mealy K, Merry C, Kyne L, Keane C, Quill R. Timing of surgery for fulminating pseudomembranous colitis. Br J Surg 1998; 85:229-231.
73. Koss K, Clark MA, Sanders DS, Morton D, Keighley MR, Goh J. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis 2006; 8:149-154.
74. Chan S, Kelly M, Helme S, Gossage J, Modarai B, Forshaw M. Outcomes following colectomy for Clostridium difficile colitis. Int J Surg 2009; 7:78-81.
75. Berman L, Carling T, Fitzgerald TN, et al. Defining surgical therapy for pseudomembranous colitis with toxic megacolon. J Clin Gastroenterol 2008; 42:476-480.
76. Jaber MR, Olafsson S, Fung WL, Reeves ME. Clinical review of the management of fulminant Clostridium difficile infection. Am J Gastroenterol 2008; 103:3195-3203.
77. Lamontagne F, Labbé AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007; 245:267-272.
78. Byl B, Jacobs F, Struelens MJ, Thys JP. Extraintestinal Clostridium difficile infections.Clin Infect Dis 1996; 22:712.
79. Ali SO, Welch JP, Dring RJ. Early surgical intervention for fulminant pseudomembranous colitis. Am Surg 2008; 74:20-26.
80. Nguyen GC, Correia AJ, Thuluvath PJ. The impact of cirrhosis and portal hypertension on mortality following colorectal surgery: a nationwide, population-based study. Dis Colon Rectum 2009; 52: 1367-1374.
81. Rayes N, Seehofer D, Hansen S, et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 2002; 74: 123-127.
82. Rayes N, Seehofer D, Theruvath T, et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial. Am J Transplant 2005;5:125-130.
83. Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005;39:540-543.
84. Kenneally C, Rosini JM, Skrupky LP, et al. Analysis of 30-day mortality for clostridium difficile-associated disease in the ICU setting. Chest 2007; 132:418-424.